Danijela Jelovac

Assistant Professor

20012019

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Danijela Jelovac is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 9 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Sharing in care: engaging care partners in the care and communication of breast cancer patients

Wolff, J. L., Aufill, J., Echavarria, D., Heughan, J. A. A., Lee, K. T., Connolly, R. M., Fetting, J. H., Jelovac, D., Papathakis, K., Riley, C., Stearns, V., Thorner, E., Zafman, N., Levy, H. P., Dy, S. M. & Wolff, A. C., Jan 1 2019, In : Breast Cancer Research and Treatment.

Research output: Contribution to journalArticle

  • A phase I trial of paclitaxel, cisplatin, and veliparib in the treatment of persistent or recurrent carcinoma of the cervix: An NRG Oncology Study (NCT#01281852)

    Thaker, P. H., Salani, R., Brady, W. E., Lankes, H. A., Cohn, D. E., Mutch, D. G., Mannel, R. S., Bell-McGuinn, K. M., Di Silvestro, P. A., Jelovac, D., Carter, J. S., Duan, W., Resnick, K. E., Dizon, D. S., Aghajanian, C. & Fracasso, P. M., 2017, In : Annals of Oncology. 28, 3, p. 505-511 7 p.

    Research output: Contribution to journalArticle

  • Whole-cell vaccines

    Jelovac, D. & Emens, L. A., Jan 1 2017, Cancer Therapeutic Targets. Springer New York, Vol. 1-2. p. 561-574 14 p.

    Research output: Chapter in Book/Report/Conference proceedingChapter

  • Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancer

    Kim, K. H., Jelovac, D., Armstrong, D. K., Schwartz, B., Weil, S. C., Schweizer, C. & Alvarez, R. D., Jan 1 2016, In : Gynecologic oncology. 140, 2, p. 210-214 5 p.

    Research output: Contribution to journalArticle